fb-pixel Skip to main content

More Life Sciences Headlines

Biogen CEO Michel Vounatsos said of his resignation, “This will be good for everyone involved,”

Biogen CEO to resign, Alzheimer’s drug sales division is dismantled

Michel Vounatsos will stay on until a replacement is found, and the Cambridge biotech will continue research on Alzheimer's despite the failure of Aduhelm.

Michel Vounatsos, Chief Executive Officer of Biogen.

Biogen CEO to step down after company’s struggles with Aduhelm

The announcement represents a stark acknowledgement that the Cambridge company has failed to find a place for a drug that was expected to drive its business for years to come.

Vertex Pharmaceuticals building in Seaport District, Boston.

Vertex stock falls after FDA halts diabetes study in surprise move

Vertex Pharmaceuticals shares tumbled after US regulators placed its study of a key new treatment for type 1 diabetes on clinical hold.

AstraZeneca’s US headquarters in Gaithersburg, Md. The pharmaceutical giant said Friday that it will open a major research center in Cambridge’s Kendall Square, the heart of the region’s biotech industry.

AstraZeneca to open major research center in Kendall Square

The pharma giant will move out of its Waltham labs and Seaport location into a new 16-story building.

A child gets a COVID-19 vaccine at Mary's Center in Washington, D.C., Nov. 3, 2021.

FDA will consider applications for young children’s vaccines in June

Moderna said it would complete its FDA application next week; Pfizer will do so in the next few weeks.

Dave Greenwalk is acting chief executive of Apertura Gene Therapy.

Apertura Gene Therapy launches with $67m to design new viruses for gene delivery

The startup is based on the work of scientists at the Broad Institute and Harvard Medical School

A chemist at Organix's research lab in Woburn.

Symeres acquires Woburn chemistry firm Organix for its lipid expertise

The Dutch buyer is one of the largest European contract research firms focused on the discovery, testing, and manufacturing of drugs.

Ginkgo Bioworks cofounder and chief executive Jason Kelly

Boston’s Ginkgo and German giant Bayer AG strike partnership

The announcement signals the winding down of Joyn Bio, a joint venture the two companies started in 2017 to explore how to make more sustainable agricultural products through biology.